Quantcast
syngoi-about-us-dna

SOLUTIONS

Our proprietary enzyme technology combined with our adaptors development platform A+ is used to develop solutions for the different therapeutical applications.

We engineer solutions to optimize the performance of DNA in advanced therapies

Our propietary enzyme technology combined with our development platform A+ is used to develop the solutions for the different therapeutical applications

AAV SYNGOI
AAV
LENTIVIRUS SYNGOI 2
Lentivirus
GENE EDITING SYNGOI
Genome Editing
DNA VACCINES SYNGOI
DNA Vaccines
mRNA SYNGOI
mRNA
NON VIRAL GENE THERAPY SYNGOI 2
Non-Viral Gene Therapy

WORKING TOGETHER TO OPTIMIZE CUSTOMER RESULTS:

Feseability

12 weeks

Goal: Optimizing functional response.

Trials with 5 selected adaptors & reference Gene.

Optimize & Scale Up

10 weeks

Goal: Optimize Scale up of the final oDNA for testing.

R&D quality oDNA for animal testing and/or IVT.

Preclinical

10 weeks

Goal: Preclinical testing & IND submission.

oDNA manufacturing & support IND submission.